{"id":"NCT00242567","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer","officialTitle":"A Phase III, Parallel Group, Randomized, Open-label, Multi-centre Clinical Trial of Zoledronic Acid in Males Receiving Androgen Deprivation Therapy for Advanced Prostate Cancer.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2005-10-20","resultsPosted":"2013-03-06","lastUpdate":"2014-05-07"},"enrollment":522,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"Zoledronic Acid","otherNames":[]},{"type":"DRUG","name":"Androgen Deprivation Therapy (ADT)","otherNames":[]}],"arms":[{"label":"Early Group","type":"EXPERIMENTAL"},{"label":"Delayed group","type":"EXPERIMENTAL"}],"summary":"This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment","primaryOutcome":{"measure":"Skeletal-related Event-free Survival in Men With Bone Metastases From Prostate Cancer","timeFrame":"18 months","effectByArm":[{"arm":"Early Group","deltaMin":58,"sd":null},{"arm":"Delayed Group","deltaMin":49,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":27,"countries":["Australia","Brazil","China","Kuwait","Lebanon","New Zealand","Saudi Arabia","South Korea","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":121,"n":259},"commonTop":["PROSTATIC SPECIFIC ANTIGEN INCREASED","BACK PAIN","CONSTIPATION","ARTHRALGIA","PAIN IN EXTREMITY"]}}